vs
Side-by-side financial comparison of CareDx, Inc. (CDNA) and LESAKA TECHNOLOGIES INC (LSAK). Click either name above to swap in a different company.
LESAKA TECHNOLOGIES INC is the larger business by last-quarter revenue ($3.0B vs $117.7M, roughly 25.4× CareDx, Inc.). CareDx, Inc. runs the higher net margin — 2.4% vs 0.0%, a 2.4% gap on every dollar of revenue. On growth, CareDx, Inc. posted the faster year-over-year revenue change (39.0% vs 0.2%). Over the past eight quarters, LESAKA TECHNOLOGIES INC's revenue compounded faster (352.8% CAGR vs 12.9%).
CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.
Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.
CDNA vs LSAK — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $117.7M | $3.0B |
| Net Profit | $2.8M | $437.0K |
| Gross Margin | — | — |
| Operating Margin | 1.0% | 2.2% |
| Net Margin | 2.4% | 0.0% |
| Revenue YoY | 39.0% | 0.2% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.05 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 26 | — | $3.0B | ||
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $178.7M | ||
| Q3 25 | $100.1M | $171.4M | ||
| Q2 25 | $86.7M | $168.5M | ||
| Q1 25 | $84.7M | $161.4M | ||
| Q4 24 | $86.6M | $176.2M | ||
| Q3 24 | $82.9M | $153.6M |
| Q3 26 | — | $437.0K | ||
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $3.6M | ||
| Q3 25 | $1.7M | $-4.3M | ||
| Q2 25 | $-8.6M | $-28.4M | ||
| Q1 25 | $-10.4M | $-22.1M | ||
| Q4 24 | $87.7M | $-32.5M | ||
| Q3 24 | $-10.6M | $-4.5M |
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 31.4% | ||
| Q3 25 | — | 30.9% | ||
| Q2 25 | — | 28.9% | ||
| Q1 25 | — | 27.5% | ||
| Q4 24 | — | 25.7% | ||
| Q3 24 | — | 22.6% |
| Q3 26 | — | 2.2% | ||
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | 1.2% | ||
| Q3 25 | -0.2% | 0.2% | ||
| Q2 25 | -12.8% | -16.7% | ||
| Q1 25 | -15.8% | 0.4% | ||
| Q4 24 | 97.5% | 0.3% | ||
| Q3 24 | -16.6% | -0.0% |
| Q3 26 | — | 0.0% | ||
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | 2.0% | ||
| Q3 25 | 1.7% | -2.5% | ||
| Q2 25 | -9.9% | -16.9% | ||
| Q1 25 | -12.2% | -13.7% | ||
| Q4 24 | 101.3% | -18.4% | ||
| Q3 24 | -12.8% | -3.0% |
| Q3 26 | — | — | ||
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | $0.04 | ||
| Q3 25 | $0.03 | $-0.05 | ||
| Q2 25 | $-0.16 | $-0.40 | ||
| Q1 25 | $-0.19 | $-0.27 | ||
| Q4 24 | $1.60 | $-0.40 | ||
| Q3 24 | $-0.20 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.9M | $1.5B |
| Total DebtLower is stronger | — | $3.2B |
| Stockholders' EquityBook value | — | — |
| Total Assets | $411.1M | $11.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 26 | — | $1.5B | ||
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $69.5M | ||
| Q3 25 | $194.2M | $72.2M | ||
| Q2 25 | $186.3M | $76.5M | ||
| Q1 25 | $230.9M | $71.0M | ||
| Q4 24 | $260.7M | $60.6M | ||
| Q3 24 | $240.9M | $49.7M |
| Q3 26 | — | $3.2B | ||
| Q1 26 | — | — | ||
| Q4 25 | — | $216.8M | ||
| Q3 25 | — | $208.1M | ||
| Q2 25 | — | $200.8M | ||
| Q1 25 | — | $194.7M | ||
| Q4 24 | — | $148.7M | ||
| Q3 24 | $0 | $148.5M |
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $180.6M | ||
| Q3 25 | $311.1M | $170.4M | ||
| Q2 25 | $327.4M | $161.6M | ||
| Q1 25 | $379.3M | $185.2M | ||
| Q4 24 | $378.4M | $193.3M | ||
| Q3 24 | $273.2M | $184.2M |
| Q3 26 | — | $11.5B | ||
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $704.6M | ||
| Q3 25 | $432.3M | $652.9M | ||
| Q2 25 | $444.3M | $653.7M | ||
| Q1 25 | $489.6M | $649.2M | ||
| Q4 24 | $491.1M | $640.6M | ||
| Q3 24 | $477.0M | $551.9M |
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 1.20× | ||
| Q3 25 | — | 1.22× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | 0.77× | ||
| Q3 24 | 0.00× | 0.81× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.3M | — |
| Free Cash FlowOCF − Capex | $514.0K | — |
| FCF MarginFCF / Revenue | 0.4% | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.54× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 26 | — | — | ||
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $-10.9M | ||
| Q3 25 | $37.4M | $8.9M | ||
| Q2 25 | $9.9M | $-9.1M | ||
| Q1 25 | $-26.6M | $10.7M | ||
| Q4 24 | $21.9M | $-9.2M | ||
| Q3 24 | $12.5M | $-4.1M |
| Q3 26 | — | — | ||
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $-14.8M | ||
| Q3 25 | — | $4.9M | ||
| Q2 25 | — | $-13.2M | ||
| Q1 25 | — | $7.8M | ||
| Q4 24 | — | $-15.5M | ||
| Q3 24 | — | $-8.1M |
| Q3 26 | — | — | ||
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | -8.3% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | -7.8% | ||
| Q1 25 | — | 4.9% | ||
| Q4 24 | — | -8.8% | ||
| Q3 24 | — | -5.3% |
| Q3 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | — | 3.6% | ||
| Q3 24 | — | 2.6% |
| Q3 26 | — | — | ||
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | -2.99× | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
LSAK
Segment breakdown not available.
